<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Impetigo — Rapid Reference Algorithm (CKS 2024)</title>
  <style>
    :root{
      --bg: #f7f9fc;
      --card: #ffffff;
      --ink: #1f2937; /* neutral, not dark-mode */
      --muted: #4b5563;
      --accent: #3b82f6; /* light blue */
      --accent-2: #60a5fa;
      --chip: #e8f1ff;
      --ok: #16a34a;
      --warn: #d97706;
      --danger: #dc2626;
      --border: #e5e7eb;
    }
    html, body{ height:100%; }
    body{
      margin:0; font-family: system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji","Segoe UI Emoji";
      background: var(--bg); color: var(--ink);
      -webkit-font-smoothing: antialiased; -moz-osx-font-smoothing: grayscale;
    }
    .wrap{max-width:1100px; margin:0 auto; padding: 28px 20px 64px;}
    header{
      display:flex; align-items:center; justify-content:space-between; gap:16px; flex-wrap:wrap;
    }
    .title{
      display:flex; align-items:center; gap:14px;
    }
    .title h1{font-size: clamp(22px, 2.4vw, 34px); line-height:1.2; margin:0;}
    .subtitle{color: var(--muted); font-size: 14px;}
    .badge{
      display:inline-flex; align-items:center; gap:8px; background: var(--chip); color: var(--accent);
      padding:8px 12px; border-radius:999px; font-weight:600; border:1px solid #dbeafe; font-size: 12px;
    }
    .btn{
      appearance:none; border:1px solid var(--border); background:#fff; color:var(--ink);
      border-radius:12px; padding:10px 14px; font-weight:600; cursor:pointer; transition:.2s box-shadow, .2s transform;
    }
    .btn:hover{ box-shadow:0 6px 22px rgba(17,24,39,.08); transform: translateY(-1px); }

    /* layout */
    .grid{ display:grid; gap:18px; }
    @media (min-width: 860px){
      .grid-2{ grid-template-columns: 1.1fr 1fr; }
      .grid-3{ grid-template-columns: repeat(3, 1fr); }
    }

    .card{
      background: var(--card); border:1px solid var(--border); border-radius:20px; padding:18px 18px 14px;
      box-shadow: 0 4px 16px rgba(31,41,55,.05);
    }
    .card h2{ font-size:18px; margin:.2rem 0 0.6rem; letter-spacing:.2px; }
    .card p, .card li{ color: var(--muted); font-size:14.5px; }
    .card ul{ margin: 0.4rem 0 0.2rem 1.1rem; }
    .card li{ margin: 6px 0; }

    /* chips */
    .chips{ display:flex; flex-wrap:wrap; gap:8px; margin:8px 0 2px; }
    .chip{ background: var(--chip); border:1px solid #dbeafe; color:#2563eb; font-weight:600; font-size:12px; padding:6px 10px; border-radius:999px; }

    /* callouts */
    .callout{ display:flex; gap:12px; align-items:flex-start; background:#fff7ed; border:1px solid #fed7aa; color:#92400e; padding:12px 14px; border-radius:14px; }
    .callout.danger{ background:#fef2f2; border-color:#fecaca; color:#991b1b; }

    /* table */
    .table{ width:100%; border-collapse:separate; border-spacing:0; overflow:hidden; border-radius:14px; border:1px solid var(--border); background:var(--card); }
    .table th, .table td{ padding:12px 12px; text-align:left; font-size:14px; }
    .table thead th{ background:#eff6ff; color:#1e3a8a; font-weight:700; border-bottom:1px solid var(--border); }
    .table tbody tr + tr td{ border-top:1px solid var(--border); }

    /* helper icons */
    .ico{ width:18px; height:18px; display:inline-block; vertical-align:-3px; }

    /* footer */
    footer{ margin-top: 16px; color: var(--muted); font-size:12px; }

    /* print */
    @media print{
      body{ background: #fff; }
      .wrap{ padding: 0; max-width: 100%; }
      header{ margin-bottom: 8px; }
      .btn{ display:none; }
      .card{ box-shadow:none; border-color:#cbd5e1; }
      .grid-2{ grid-template-columns: 1fr 1fr !important; }
      .table thead th{ background:#e5f0ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .badge{ border-color:#cfe0ff; background:#eaf2ff; }
    }
  </style>
</head>
<body>
  <div class="wrap">
    <header>
      <div class="title">
        <svg class="ico" viewBox="0 0 24 24" fill="none" aria-hidden="true">
          <path d="M12 3l7 4v5c0 5-3.5 8.5-7 9-3.5-.5-7-4-7-9V7l7-4z" stroke="#3b82f6" stroke-width="1.5" fill="#dbeafe"/>
          <circle cx="12" cy="12" r="2.2" fill="#3b82f6"/>
        </svg>
        <div>
          <h1>Impetigo — Rapid Reference Algorithm</h1>
          <div class="subtitle">CKS (Last revised July 2024) · For quick use during consultations</div>
        </div>
      </div>
      <div>
        <span class="badge">Primary care · All ages</span>
        <button class="btn" onclick="window.print()">Print one‑pager</button>
      </div>
    </header>

    <div class="grid grid-2" style="margin-top:16px;">
      <section class="card">
        <h2>1) Diagnosis — clinical</h2>
        <ul>
          <li><strong>Non‑bullous:</strong> golden‑brown crusts (face/limbs), minimal erythema, usually no systemic features.</li>
          <li><strong>Bullous:</strong> large flaccid bullae → collarette of scale after rupture; trunk/flexures; systemic features if extensive.</li>
          <li><strong>Swab if</strong> recurrent/widespread, poor response, diagnostic uncertainty, or suspected MRSA.</li>
        </ul>
        <div class="chips" aria-label="history and exam">
          <span class="chip">Hx: onset, sites, trauma</span>
          <span class="chip">Comorbids (eczema/DM)</span>
          <span class="chip">Systemic Sx</span>
          <span class="chip">Check differentials</span>
        </div>
      </section>

      <section class="card">
        <h2>2) Red flags / Referral</h2>
        <div class="callout danger">
          <svg class="ico" viewBox="0 0 24 24" fill="none" aria-hidden="true"><path d="M12 3l9 16H3L12 3z" stroke="#dc2626" stroke-width="1.5"/><path d="M12 9v5m0 3.5h.01" stroke="#dc2626" stroke-width="1.5"/></svg>
          <div>
            <strong>Admit / urgent referral if</strong>: sepsis or deep soft tissue infection; immunosuppressed + widespread.
            <br/><strong>Consider referral / advice if</strong>: systemically unwell, frequent recurrence, high‑risk of complications, uncertain diagnosis. Suspected MRSA → discuss with microbiology.
          </div>
        </div>
      </section>

      <section class="card">
        <h2>3) Universal measures</h2>
        <ul>
          <li>Hygiene: wash lesions, avoid scratching, keep covered; hand hygiene; no sharing towels/linens; clean toys/equipment.</li>
          <li>Laundry ≥ 60 °C daily for first few days.</li>
          <li>Exclude from school/work until lesions healed & crusted <em>or</em> 48 h after starting treatment (including H<sub>2</sub>O<sub>2</sub> cream).</li>
          <li>Treat predisposing skin disease (eczema, lice, scabies, insect bites).</li>
        </ul>
      </section>

      <section class="card">
        <h2>4) Treatment pathway</h2>
        <ul>
          <li><strong>Non‑bullous — Localized, not unwell:</strong> 
            <span class="chip">Hydrogen peroxide 1% cream</span> 2–3×/day × 5 days → if unsuitable <span class="chip">Fusidic acid 2% TDS</span> × 5 days → if resistance suspected/confirmed <span class="chip">Mupirocin 2% TDS</span> × 5 days.
          </li>
          <li><strong>Non‑bullous — Widespread, not unwell:</strong> Topical <em>or</em> oral antibiotic (do <u>not</u> combine).</li>
          <li><strong>Non‑bullous — Systemically unwell / high‑risk:</strong> Oral antibiotic.</li>
          <li><strong>Bullous impetigo:</strong> Oral antibiotic (5 days; consider 7 days if severe/very numerous lesions).</li>
        </ul>
      </section>
    </div>

    <section class="card" style="margin-top:18px;">
      <h2>5) Oral antibiotic choices</h2>
      <table class="table" role="table" aria-label="Oral antibiotic choices">
        <thead>
          <tr>
            <th>Population</th>
            <th>First line</th>
            <th>Penicillin allergy / alternative</th>
            <th>Notes</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td><strong>Adults</strong></td>
            <td>Flucloxacillin 500 mg QDS × 5 days</td>
            <td>Clarithromycin 250 mg BD × 5 days (↑500 mg BD if severe).<br/>If pregnant + penicillin‑allergic: Erythromycin 250–500 mg QDS × 5 days.</td>
            <td>Consult microbiology if suspected/confirmed MRSA.</td>
          </tr>
          <tr>
            <td><strong>Children & young people</strong></td>
            <td>Flucloxacillin PO (age‑based):<br/>1 m–1 y: 62.5–125 mg QDS × 5 d<br/>2–9 y: 125–250 mg QDS × 5 d<br/>10–17 y: 250–500 mg QDS × 5 d</td>
            <td>Clarithromycin PO:<br/>1 m–11 y: 7.5 mg/kg BD (or 62.5–250 mg BD by weight bands) × 5 d<br/>12–17 y: 250 mg BD × 5 d (↑500 mg BD if severe)</td>
            <td>Pregnant + penicillin‑allergic (8–17 y): Erythromycin 250–500 mg QDS × 5 days.</td>
          </tr>
        </tbody>
      </table>
      <p style="margin-top:8px; color:var(--muted); font-size:13px;">Typical course 5 days; may extend to 7 days by clinical judgement. Follow BNF/eMC for cautions, interactions and renal/hepatic dosing.</p>
    </section>

    <div class="grid grid-3" style="margin-top:18px;">
      <section class="card">
        <h2>6) Reassess / Follow‑up</h2>
        <ul>
          <li>Reassess if rapid worsening or no improvement after a completed course.</li>
          <li>Check adherence + hygiene; revisit differential diagnoses and complications.</li>
          <li>Consider swab for C&amp;S (esp. after oral therapy / recurrent cases).</li>
          <li>Adjust to narrow‑spectrum per C&amp;S; consider decolonisation if recurrent (nasal swab, local protocol).</li>
        </ul>
      </section>
      <section class="card">
        <h2>Memory aide</h2>
        <ul>
          <li><strong>Localized non‑bullous</strong> → topical (H<sub>2</sub>O<sub>2</sub> first).</li>
          <li><strong>Widespread or bullous</strong> → oral antibiotic.</li>
          <li><strong>No dual</strong> topical + oral in routine cases.</li>
          <li><strong>Always</strong> hygiene + temporary exclusion.</li>
        </ul>
      </section>
      <section class="card">
        <h2>Differentials (think)</h2>
        <ul>
          <li>Cellulitis, erysipelas, SSSS, necrotising fasciitis.</li>
          <li>Tinea/candidiasis, scabies, HSV, VZV.</li>
          <li>Contact/atopic dermatitis, insect bites, burns.</li>
          <li>Pemphigus, bullous pemphigoid, EM, Sweets.</li>
        </ul>
      </section>
    </div>

    <footer>
      Source: User‑provided NICE CKS Impetigo guidance (reviewed Dec 2023; last revised July 2024). This quick reference is for healthcare professionals and does not replace clinical judgement.
    </footer>
  </div>
</body>
</html>